Coya Therapeutics, Inc.
COYAHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, Coya Therapeutics, Inc. (COYA) is listed under Biotechnology. With a market capitalization of $106.7M, it sits in micro-cap territory. Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Market Cap
$106.7M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
-2.49
EPS (TTM)
$-1.18
EPS (Fwd)
$-1.83
ROE
-51.3%
ROA
-27.6%
Cash
$50.7M
Total Debt
$0
Free CF
-$9.7M
52W Change
-20.0%
Annual Financials
Cash vs Debt
Where COYA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, COYA finished 0.83% above its 150-day moving average ($4.83) and 5.62% below its 200-day moving average ($5.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COYA overbought or oversold?
At the July 15, 2026 close, COYA's RSI(14) was 40.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Coya Therapeutics, Inc. reports $50.7M in cash and $0 in total debt. Free cash flow is running at -$9.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -51.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Coya Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Coya Therapeutics, Inc. and its sector.